Krka’s EBITDA Margin Slumps Despite Record H1 Sales

Follows Russian Inventory Purchases Necessary For Long-Term Supply

Krka has explained a near double-digit percentage point drop for its EBITDA margin, as it presented preliminary results for the first half of 2022.

Russia map close up with magnifier
Russia is Krka's largest individual market • Source: Shutterstock

Krka Group’s EBITDA margin is to plummet by more than nine percentage points as reported for the first half of 2022, from 31.5% to 22.4%, as a result of the Slovenian firm increasing inventories of raw materials, materials, bulk products, and products required for “long-term uninterrupted supply of Krka’s pharmaceuticals in the Russian market.”

Announcing the Krka group’s unaudited business results and main operating estimates for the first half of this year, Krka has...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business